The Acute Disease Quality Initiative (ADQI) 16 Workgroup has developed consensus definitions, staging criteria, and management strategies for acute kidney disease (AKD), which is a condition that follows acute kidney injury (AKI). AKD is defined as kidney damage or loss of function lasting between 7 and 90 days after an AKI event. Recovery from AKD is defined as a reduction in AKI stage and can be further refined by changes in serum creatinine, glomerular filtration rate, biomarkers of injury or repair, and/or return of renal reserve. The workgroup also proposes a staging system for AKD, which includes stages 0A, 0B, and 0C, representing different levels of recovery and ongoing kidney damage. AKD is a continuum of disease that can lead to chronic kidney disease (CKD). Persistent AKI is associated with worse outcomes, including increased risk of CKD and mortality. The workgroup recommends that patients with persistent AKI be closely monitored and evaluated to determine the need for renal replacement therapy (RRT). They also emphasize the importance of identifying patients at risk of persistent AKI and developing strategies to improve outcomes. The workgroup highlights the need for further research to better understand the underlying processes of AKD and to develop effective management strategies. They propose research recommendations, including the development of clinical tools to assess kidney function in AKI, the evaluation of alternative approaches to estimate glomerular filtration rate, and the identification of biomarkers that can predict outcomes in AKD. The workgroup also emphasizes the importance of follow-up care for patients with AKD. They propose a layered approach to follow-up care, with the intensity of care proportional to the risk of future outcomes. Patients with more severe or persistent AKD, those with premorbid conditions that increase the risk of CKD progression, and those with recurrent disease or non-recovery may benefit from earlier or more frequent surveillance. The workgroup also discusses the use of RRT in patients with CKD, noting that the decision to initiate RRT is not standardized and can vary based on the severity of renal dysfunction. They suggest that RRT can be used as a marker of AKI severity, although it may also include patients with less severe AKI. The workgroup recommends that patients with AKD be closely monitored and evaluated to determine the need for RRT and to improve outcomes.The Acute Disease Quality Initiative (ADQI) 16 Workgroup has developed consensus definitions, staging criteria, and management strategies for acute kidney disease (AKD), which is a condition that follows acute kidney injury (AKI). AKD is defined as kidney damage or loss of function lasting between 7 and 90 days after an AKI event. Recovery from AKD is defined as a reduction in AKI stage and can be further refined by changes in serum creatinine, glomerular filtration rate, biomarkers of injury or repair, and/or return of renal reserve. The workgroup also proposes a staging system for AKD, which includes stages 0A, 0B, and 0C, representing different levels of recovery and ongoing kidney damage. AKD is a continuum of disease that can lead to chronic kidney disease (CKD). Persistent AKI is associated with worse outcomes, including increased risk of CKD and mortality. The workgroup recommends that patients with persistent AKI be closely monitored and evaluated to determine the need for renal replacement therapy (RRT). They also emphasize the importance of identifying patients at risk of persistent AKI and developing strategies to improve outcomes. The workgroup highlights the need for further research to better understand the underlying processes of AKD and to develop effective management strategies. They propose research recommendations, including the development of clinical tools to assess kidney function in AKI, the evaluation of alternative approaches to estimate glomerular filtration rate, and the identification of biomarkers that can predict outcomes in AKD. The workgroup also emphasizes the importance of follow-up care for patients with AKD. They propose a layered approach to follow-up care, with the intensity of care proportional to the risk of future outcomes. Patients with more severe or persistent AKD, those with premorbid conditions that increase the risk of CKD progression, and those with recurrent disease or non-recovery may benefit from earlier or more frequent surveillance. The workgroup also discusses the use of RRT in patients with CKD, noting that the decision to initiate RRT is not standardized and can vary based on the severity of renal dysfunction. They suggest that RRT can be used as a marker of AKI severity, although it may also include patients with less severe AKI. The workgroup recommends that patients with AKD be closely monitored and evaluated to determine the need for RRT and to improve outcomes.